Last reviewed · How we verify
NCT05582603: CCTLongCOVID
Safety and Dosage of a Computerized Cognitive Training Program for Cognitive Dysfunction After COVID-19
Phase 1, PHASE2 trial testing CCT Long COVID in Post-Acute COVID-19 in 20 participants. Status unknown.
30 November 2022
Quick facts
| Lead sponsor | Universidad Antonio de Nebrija |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 18 October 2022 |
| Primary completion | 30 November 2022 |
| Estimated completion | 30 November 2022 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- CCT Long COVID
Conditions studied
- Post-Acute COVID-19 — all drugs for Post-Acute COVID-19 →
- Post Acute COVID-19 Syndrome — all drugs for Post Acute COVID-19 Syndrome →
- Cognitive Dysfunction — all drugs for Cognitive Dysfunction →
- Cognitive Impairment — all drugs for Cognitive Impairment →
Sponsor
Universidad Antonio de Nebrija
Who can join
Adults 25 to 55, any sex, with Post-Acute COVID-19 or Post Acute COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this Phase I/II clinical trial is to assess the safety and maximum tolerated training time of a self-administered computerized cognitive training (CCT) in individuals with cognitive dysfunction as a consequence of COVID-19 infection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05582603
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Post-Acute COVID-19
Currently open trials in the same condition.
- NCT07140094 — Long-Covid-19 Alleviation Through Learning Mindfulness Study · NA · recruiting
- NCT06161688 — Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID · Phase 2 · active not recruiting
- NCT05877508 — Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19) · Phase 2 · active not recruiting
- NCT05866952 — Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection · recruiting
- NCT05745805 — Cohort Follow-up of Epidemic and Neuroimaging for Patients During the 1st Wave of the COVID-19 in China · recruiting
Other Universidad Antonio de Nebrija trials
Trials by the same sponsor.
- NCT05571852 — Personalized Computerized Training Program for Cognitive Dysfunction After COVID-19 · NA · completed
- NCT05050292 — Cognitive Stimulation and Sleep Quality. An Innovative Intervention for Insomnia · NA · unknown
- NCT04299672 — Cervical Functionality and Posture (CERFUPOS) · NA · completed
- NCT03516344 — Effect of Osteopathic Manipulations on Portal Venous Flow · NA · completed
- NCT04110509 — Fragility and Programmed Cardiovascular Surgery (EcoSarco) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05582603 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad Antonio de Nebrija
- Last refreshed: 18 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05582603.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing